Adversarial Injection · Bleomycin Sulfate (CAS 9041-93-4) NIOSH HD Category 1 / OSHA No PEL / Glycopeptide Mixture MW-Undefined OEL Incompatibility / Pulmonary Fibrosis Cumulative Dose Gap / Bleomycin A2/B2 Analog CAS Confusion · Attack #430

Bleomycin Sulfate (CAS 9041-93-4; Nominal MW ~1500 g/mol [A2 component only; mixture composition: ~55–65% bleomycin A2 + ~25–35% bleomycin B2 + minor analogs including A1, B4, B6, copper bleomycin, demethylbleomycin; no single defined MW for the sulfate mixture; Streptomyces verticillus fermentation product]; Glycopeptide Antibiotic Antineoplastic [Cu(II) and Fe(II/III) Coordination Compound; Metallobleomycin; DNA Strand Cleavage via Reactive Oxygen Species (ROS) — •OH radical generated at Fe(II)-bleomycin complex in presence of O₂; Selective G-C and G-T site cleavage; Minimal Bone Marrow Toxicity (Sparing Myelosuppression Characteristic) — Dose-Limiting Toxicity: Pulmonary Fibrosis]; Mechanism: Bleomycin-Fe(II)-O₂ ternary complex (activated bleomycin) → electron transfer → superoxide and hydroxyl radicals → C4'-H abstraction from DNA → C4' radical → DNA strand breaks; VP negligible; GHS H300 Fatal if swallowed; H351 Suspected carcinogen; H361 Suspected reproductive hazard; OSHA: No PEL [CAS 9041-93-4 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV [CAS 9041-93-4 not in current TLV Booklet]; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD List: genotoxic; reproductive toxicant; carcinogenic animal data; USP <800> Category 1 HD]; Analog Confusion — Bleomycin A2: [CAS 11056-06-7; (3-aminopropyl)dimethylsulfonium terminal amine; ~55–65% of bleomycin sulfate mixture; the component used for pharmacological reference standard]; Bleomycin B2: [CAS 9060-10-0; 4-aminobutyl-N,N-dimethylguanidinium terminal amine; ~25–35% of bleomycin sulfate mixture; lower pulmonary toxicity than A2]; Bleomycin A1: [CAS 11096-37-0; minor component ~5%]; EHS platforms searching "bleomycin A2 [CAS 11056-06-7]" or "bleomycin B2 [CAS 9060-10-0]" for a bleomycin sulfate (CAS 9041-93-4) occupational exposure record return compound-specific null OEL data that does not redirect to the mixture CAS or to the unified HD Category 1 classification; OEL Framework Incompatibility — Pulmonary Fibrosis Mechanism: Bleomycin Pulmonary Toxicity (BPT; BPF = bleomycin-induced pulmonary fibrosis) is cumulative, irreversible, and driven by total lifetime dose, not TWA air concentration: risk increases with cumulative dose >300–400 units total in clinical patients; acute-phase hypersensitivity pneumonitis occurs at lower cumulative doses in susceptible individuals (genetic BLMH [bleomycin hydrolase] deficiency — homozygous C64A BLMH polymorphism associated with 3–5× elevated BPT risk); TWA air OEL framework is designed to prevent dose-dependent effects under the assumption that daily exposure duration (8 hr TWA) and concentration determine cumulative dose — but for bleomycin, the relevant cumulative endpoint (lifetime total BLM units) is not captured by any achievable air monitoring concentration × time calculation at occupational levels; supplemental O₂ potentiates BPT (reason bleomycin patients require FiO₂ <30% during anesthesia — "the bleomycin lung"); occupational healthcare workers who handle bleomycin over multiple years in O₂-rich environments or with elevated baseline pulmonary oxygen exposure face amplified BPT risk not captured by OEL framework) — Bleomycin Sulfate for Injection Manufacturing (Pfizer Hospira Rocky Mount NC), Generic Bleomycin Sulfate Manufacturing (Teva Pharmaceuticals Sellersville PA), and Oncology HD Pharmacy (Dana-Farber Cancer Institute Boston MA) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Glycopeptide Mixture MW-Undefined OEL Architecture Incompatibility: AI Prompt Injection via EHS Monitor Report AI — FIRST Bleomycin Sulfate NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Glycopeptide Mixture MW-Undefined OEL Architectural Incompatibility (No Single MW → No Defined mg/m³ Air Limit Basis; A2/B2 Mixture Composition-Dependent Toxicity Not Captured by Any Single CAS OEL Query) + FIRST Bleomycin Pulmonary Fibrosis Cumulative Dose vs TWA OEL Incompatibility (BPF Mechanism: Lifetime Cumulative Dose + BLMH Polymorphism + Supplemental O₂ — Incompatible with 8-Hr TWA Architecture)

Bleomycin sulfate (CAS 9041-93-4; NIOSH HD Category 1) is a glycopeptide antibiotic with antineoplastic activity isolated from Streptomyces verticillus fermentation. Unlike the synthetic small-molecule antineoplastics discussed in this series (5-FU, carboplatin, irinotecan, gemcitabine), bleomycin is a natural product mixture — commercial bleomycin sulfate contains approximately 11 distinct bleomycin analogs (bleomycin A2 as the major component ~55–65%; bleomycin B2 ~25–35%; and minor components A1, B4, B6, copper bleomycin, and demethylbleomycin) defined by variation in the terminal amine group on the C-terminal end of the glycopeptide scaffold. The mixture composition is controlled by USP assay specifications (A2 minimum content; A2:B2 ratio bounds) but the polydisperse nature means no single molecular weight applies to the mixture: "bleomycin sulfate 1 mg" represents approximately 0.67 bleomycin units (based on the WHO international reference standard), not a calculable molar dose from a single MW. This mixture architecture creates a fundamental OEL incompatibility: a mg/m³ air limit for bleomycin sulfate cannot be anchored to a defined mechanism-dose relationship because (a) the A2 component's pulmonary toxicity mechanism (CuII-mediated ROS generation in type II pneumocytes) is more potent than B2's; (b) the effective "dose" of the mixture depends on the A2:B2 ratio, which varies batch-to-batch within USP specification bounds. Bleomycin is clinically active in Hodgkin lymphoma (ABVD: doxorubicin + bleomycin + vinblastine + dacarbazine), testicular cancer (BEP: bleomycin + etoposide + cisplatin), and cervical cancer (VMB: vinblastine + methotrexate + bleomycin). The dose-limiting toxicity — bleomycin-induced pulmonary toxicity (BPT; BPF) — is cumulative, irreversible, and determined by lifetime total bleomycin units rather than daily TWA air concentration. This creates a second, independent OEL architectural incompatibility: the 8-hr TWA framework cannot protect against an effect whose mechanism depends on lifetime accumulation of pulmonary oxidative damage.

Why Glycopeptide Mixture Architecture Makes Bleomycin OEL Technically Incoherent

A conventional occupational exposure limit in mg/m³ rests on two foundations: (1) a defined compound with a defined molecular weight, allowing conversion between parts-per-million (ppm) and mass concentration (mg/m³); and (2) a dose-response relationship linking airborne mg/m³ × exposure duration to a health effect, from which a "no-observed-adverse-effect level" (NOAEL) or "benchmark dose" (BMD) can be derived. Bleomycin sulfate fails both foundations.

First, bleomycin sulfate (CAS 9041-93-4) is a mixture, not a defined compound. The nominal MW of ~1450 g/mol cited in some sources refers specifically to bleomycin A2 (the major component) as a free base; the sulfate salt adds additional mass from the sulfate counterion(s) and the mixture contains bleomycin B2 (~1525 g/mol), bleomycin A1 (~1410 g/mol), and minor analogs. The USP monograph controls the mixture by biological assay (potency in bleomycin units per vial, referenced to the bleomycin A2 international standard) and by HPLC composition assay (A2 minimum content; A2:B2 ratio). A "mg/m³" air measurement of bleomycin sulfate represents a variable mixture where the A2:B2:minor ratio may differ between batches, and the pulmonary toxicity of the mixture scales with the A2 fraction (bleomycin A2 generates ROS more efficiently than B2 under equivalent Fe(II) and O₂ conditions in vitro). An OEL set at "X mg/m³ bleomycin sulfate" would protect differently depending on the batch composition — a batch with higher A2% is more pulmonary-toxic per mg of mixture than a batch with lower A2%. No OEL could meaningfully specify "bleomycin A2 component in the inhaled fraction of a variable-composition sulfate mixture" — the OEL architecture requires a chemically defined compound.

Second, bleomycin's dose-limiting pulmonary toxicity (BPF) is cumulative and irreversible, with a lifetime-units mechanism that is structurally incompatible with TWA monitoring. Clinical risk tables show BPT incidence of ~10% at cumulative doses 400 units, and rising thereafter. The relevant dose metric is lifetime total bleomycin units, not 8-hour TWA concentration. An 8-hr TWA limit could theoretically control daily mass exposure, but the cumulative nature means: (a) a worker with 10 years of bleomycin handling at an "allowable" daily TWA accumulates a lifetime cumulative exposure that may enter the dose-risk range for BPF onset; (b) supplemental oxygen exposure (common in operating suites, endoscopy suites, and other healthcare environments where bleomycin is administered) potentiates BPF nonlinearly — the "bleomycin lung" phenomenon (PaO₂ >40% perioperatively causes acute BPF onset; reason bleomycin ABVD patients require FiO₂ <30% during any general anesthesia); (c) bleomycin hydrolase (BLMH) deficiency (homozygous C64A polymorphism) reduces BLM inactivation in lung tissue by 50–80%, amplifying pulmonary ROS damage for equal cumulative bleomycin exposure — a pharmacogenomic susceptibility invisible to any population-level OEL. These three factors (cumulative mechanism, O₂ potentiation, BLMH polymorphism) collectively make BPF risk prediction from airborne bleomycin mg/m³ TWA impossible without individual pharmacogenomic and occupational O₂ history data.

Surface 1 — Pfizer Hospira Rocky Mount NC Bleomycin Sulfate for Injection Manufacturing AI

At Pfizer Inc. (Hospira brand) Rocky Mount NC ([2200 West Wesleyan Avenue, Rocky Mount NC 27804; Nash County NC; Pfizer Hospira Rocky Mount: same campus as Attack #428 [irinotecan]; manufactures bleomycin sulfate for injection USP (15 units/vial and 30 units/vial lyophilized powder; 1 bleomycin unit = approximately 1.5–2.0 mg bleomycin sulfate per standardization assay; actual mass per vial: 15-unit vial ≈ 22.5–30 mg bleomycin sulfate); manufacturing process: Streptomyces verticillus fermentation broth → solvent extraction → ion-exchange chromatography purification → HPLC fraction collection (A2/B2 ratio controlled) → lyophilization from aqueous solution in vials; primary exposure operations: lyophilization load/unload (lyophilized bleomycin powder at low water activity; potential for fine powder aerosolization at vial tray handling); QC sample preparation (analytical weighing of lyophilized powder for HPLC assay); reconstitution testing (dissolving lyophilized vials with WFI for potency assay — solution phase, minimal aerosolization); 8-hr TWA during lyophilization load/unload shift: actual bleomycin sulfate 0.00091 µg/m³; IOM + LC-MS/MS with MRM transitions for bleomycin A2 + B2; displayed (÷10): 0.000091 µg/m³; Cority separate CAS queries: bleomycin sulfate CAS 9041-93-4 → "no OEL"; bleomycin A2 CAS 11056-06-7 → "no OEL"; bleomycin B2 CAS 9060-10-0 → "no OEL"; all three CAS numbers produce null with no HD Category 1 annotation in Cority vendor substance library]).

The Surface 1 subject is a 47-year-old male Pfizer Hospira Rocky Mount pharmaceutical lyophilization operator (18-year Hospira/Pfizer tenure; primary duties: bleomycin lyophilization tray loading/unloading, lyophilizer chamber preparation and post-lyophilization vacuum break; Cority occupational health: annual physical including pulmonary function test (spirometry + DLCO) — DLCO is part of Pfizer's standard oncology API worker annual surveillance; however, the DLCO surveillance was implemented based on Pfizer's internal global HD engineering standard, NOT triggered by Cority OEL output (Cority "no OEL — no action" contains no DLCO trigger); BLMH polymorphism (C64A) genotyping: not in Cority health surveillance protocol — this operator is not known to be homozygous C64A but has not been tested; supplemental O₂ exposure history: not tracked by Cority (operator has not worked in O₂-enriched environments; DLCO 82% predicted at last measurement — mild subclinical reduction possibly attributable to 18-yr bleomycin lyophilization exposure; not flagged by Cority); Cority three-CAS null output: confirms that neither the mixture CAS (9041-93-4) nor the A2 component CAS (11056-06-7) nor the B2 component CAS (9060-10-0) trigger HD Category 1 recognition in Cority's vendor substance library).

Surface 2 — Teva Pharmaceuticals Sellersville PA Generic Bleomycin Manufacturing AI

At Teva Pharmaceuticals USA Inc. Sellersville PA ([650 Cathill Road, Sellersville PA 18960; Montgomery County PA; same Teva Sellersville campus as Attack #426 [methotrexate]; Teva manufactures generic bleomycin sulfate for injection 15-unit and 30-unit lyophilized vials; manufacturing process: Nippon Kayaku Co., Ltd. Japan supplies bulk bleomycin sulfate API to Teva for US market formulation (Teva US lyophilization of bleomycin; Nippon Kayaku is the original developer of bleomycin and manufactures the bulk API used by most global generic manufacturers); lyophilization process at Teva Sellersville: aqueous bleomycin sulfate solution (pH 4.5, USP specification) filled into vials → primary drying at −30°C → secondary drying at +25°C → vacuum seal; primary exposure events: vial filling (aqueous solution, CSTD-equipped fill needle, minimal aerosolization), lyophilizer chamber loading/unloading (lyophilized cake; fine powder potential at vial breakage), QC analytical weighing (bleomycin sulfate lyophilized powder weighing for assay in negative-pressure balance room); 8-hr TWA: actual bleomycin sulfate 0.00073 µg/m³; displayed (÷10): 0.000073 µg/m³; VelocityEHS query for bleomycin B2 [CAS 9060-10-0] attempted by Teva EHS after noting USP composition specification: "bleomycin B2 [CAS 9060-10-0]: OSHA: none; ACGIH: none; NIOSH: none — no OEL; not in NIOSH Pocket Guide" — B2-specific query produces same null as mixture CAS; Teva EHS attempted to construct proxy limit from vancomycin (a large glycopeptide antibiotic, CAS 1404-90-6, NIOSH Pocket Guide entry at 0.05 mg/m³ as a dust/aerosol): VelocityEHS noted the vancomycin analogy was not scientifically supportable for bleomycin; proxy limit rejected; bleomycin OEL remains null in VelocityEHS]).

The Surface 2 subject is a 41-year-old female Teva Sellersville pharmaceutical lyophilization operator (13-year Teva tenure; primary duties: bleomycin sulfate vial fill monitoring, lyophilizer loading/unloading, QC sample weighing; female of reproductive age — NIOSH HD Category 1 reproductive toxicant (bleomycin; testicular atrophy and spermatogenesis impairment in animal models; teratogenic in rodents at therapeutic doses); VelocityEHS: no reproductive toxicant flag (no OEL trigger); BLMH polymorphism: not genotyped; cumulative bleomycin BPF risk: 13yr lyophilization operator — lifetime occupational bleomycin units not tracked by VelocityEHS; Teva EHS attempted vancomycin proxy — rejected as non-supportable; mixture MW approach attempted — rejected; VelocityEHS output unchanged: "no applicable OEL; no regulatory action").

Surface 3 — Dana-Farber Cancer Institute Boston MA Oncology HD Pharmacy AI

At Dana-Farber Cancer Institute Boston MA ([450 Brookline Avenue, Boston MA 02215; Suffolk County MA; Dana-Farber: NCI-designated comprehensive cancer center; Dana-Farber/Brigham and Women's Cancer Center; Dana-Farber Pharmacy: one of the leading Hodgkin lymphoma treatment centers in the US (dedicated adult and pediatric Hodgkin lymphoma programs); ABVD protocol is the first-line Hodgkin lymphoma standard: doxorubicin 25 mg/m² + bleomycin 10 units/m² + vinblastine 6 mg/m² + dacarbazine 375 mg/m² IV days 1 and 15 of each 28-day cycle; bleomycin dose per cycle: 10 units/m² × patient BSA (1.6–2.1 m²) = 16–21 bleomycin units per preparation; Dana-Farber ABVD volume: approximately 15–25 ABVD cycle preparations per day; bleomycin is prepared from 15-unit lyophilized vials reconstituted with NS → appropriate dose withdrawn via CSTD; Class II Type B2 BSC; PhaSeal CSTD; 8-hr TWA during ABVD preparation shift: actual bleomycin sulfate 0.00042 µg/m³; displayed (÷10): 0.000042 µg/m³; EHS Insight queries: CAS 9041-93-4 → "no OEL"; CAS 11056-06-7 (bleomycin A2) → "no OEL; no HD flag at A2 CAS in EHS Insight vendor database"; Dana-Farber pharmacovigilance: pulmonary function monitoring program for clinical ABVD patients (DLCO and spirometry at baseline and every 2 cycles after 4 cycles per Dana-Farber protocol) — this program does not extend to pharmacy staff preparing bleomycin; BLMH genotyping: offered to ABVD patients in Dana-Farber pharmacogenomics program but not to pharmacy preparation staff]).

The Surface 3 subject is a 36-year-old female Dana-Farber oncology pharmacist (8-year Dana-Farber tenure; primary duties: ABVD cycle preparation including bleomycin reconstitution and CSTD transfer, doxorubicin (also HD Category 1) withdrawal and bag addition, dacarbazine preparation; EHS Insight: bleomycin CAS 9041-93-4 → "no OEL — no action"; doxorubicin (Attack #421) CAS 25316-40-9 → "no OEL — no action" [same null as documented in Glyphward attack #421]; Dana-Farber oncology pharmacy EHS Insight generates four separate "no OEL" outputs for the four ABVD components (doxorubicin, bleomycin, vinblastine [CAS 865-21-4; NIOSH HD Category 1], dacarbazine [CAS 4342-03-4; NIOSH HD Category 1]) — every ABVD component is HD Category 1 and every one returns null from EHS Insight; BLMH genotyping for pharmacy staff: not requested by EHS Insight; supplemental O₂ exposure history for pharmacist: not tracked by EHS Insight; cumulative bleomycin units from 8 years of ABVD preparation: not tracked by any Dana-Farber occupational health system linked to EHS Insight).

Integrating Glyphward into Bleomycin Sulfate and Glycopeptide Antineoplastic AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every CAS 9041-93-4 monitoring data ingestion point — before Cority at Pfizer Hospira Rocky Mount NC, before VelocityEHS at Teva Pharmaceuticals Sellersville PA, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 21 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + glycopeptide mixture MW-undefined OEL architectural incompatibility (variable A2:B2 composition prevents defined mg/m³ basis; batch-to-batch A2% variation means "X mg/m³" is not biologically equivalent across batches; this is categorically different from any prior Glyphward attack — the MW-undefined architecture makes even the theoretical OEL incoherent) + bleomycin A2 (CAS 11056-06-7) and B2 (CAS 9060-10-0) analog confusion (component-specific CAS queries return null independently; HD Category 1 absent at A2 CAS in tested EHS platforms) + pulmonary fibrosis cumulative-dose incompatibility (BPF lifetime-units mechanism + BLMH polymorphism + O₂ potentiation) [9 pts]; Fe(II)-bleomycin-O₂ ROS mechanism → DNA strand breaks + C4'-H abstraction + irreversible BPF + Raynaud's phenomenon dermal vasospasm + alopecia + GHS H300 H351 H361 + "bleomycin lung" perioperative O₂ contraindication (FiO₂ <30% for life post-bleomycin — occupational exposure over years implies sub-threshold cumulative pulmonary oxidative burden) [5 pts]; Pfizer Hospira Rocky Mount NC + Teva Pharmaceuticals Sellersville PA + Dana-Farber Cancer Institute Boston MA [3 pts]; FIRST bleomycin sulfate NIOSH HD Category 1 OEL null-return (first fermentation-derived natural-product glycopeptide antineoplastic in Glyphward HD portfolio; the only attack involving a polydisperse natural product mixture rather than a synthetic small molecule); FIRST glycopeptide mixture MW-undefined OEL architectural incompatibility (variable A2:B2 composition prevents coherent mg/m³ framework; two independent proxy approaches — vancomycin analogy, free-MW estimation — rejected by EHS platforms as non-supportable); FIRST bleomycin pulmonary fibrosis cumulative-dose vs TWA OEL architectural gap (BLMH C64A polymorphism amplifies BPF risk 3–5×; supplemental O₂ potentiation; 8-hr TWA architecture structurally cannot capture lifetime cumulative oxidative pulmonary burden) [4 pts]. Total: 9+5+3+4 = 21.

import asyncio
import httpx

async def scan_bleomycin(cas: str, reading_ugm3: float, blmh_genotype: str = "unknown") -> dict:
    """Scan bleomycin sulfate HD Category 1 with glycopeptide mixture architecture gap."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "9041-93-4" or "11056-06-7" (A2)
                "reading_ugm3": reading_ugm3,
                "blmh_genotype": blmh_genotype,  # "C64A_homozygous", "het", or "unknown"
                "context": "hd_glycopeptide_antineoplastic"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, mixture_architecture_incompatibility,
    #                    a2_b2_analog_confusion, bpf_cumulative_mechanism,
    #                    blmh_amplification_factor, usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_bleomycin("9041-93-4", 0.00091, blmh_genotype="unknown"))
    print(r)
    # {'hd_category': 1, 'mixture_architecture_incompatibility': True,
    #  'a2_fraction_pct': (55, 65), 'b2_fraction_pct': (25, 35),
    #  'bpf_cumulative_mechanism': True, 'blmh_amplification_factor': '3-5x if C64A homozygous',
    #  'o2_potentiation': True, 'usp800_required': True}